Data through Oct 29, 2026 Snapshot Oct 29, 7:00 PM ET
GLUE
GLUE
Monte Rosa Therapeutics
$10.87
−$8.03(−42.49%)•
Gene's position
Shares529.1005
Cost basis$10,000.00
Bought at$18.90
Last close$10.87
Current value$5,751.32
Total return−42.49%
About
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment…